We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care

By HospiMedica International staff writers
Posted on 08 May 2025

Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. More...

With EDs often being some of the busiest areas in hospitals, this presents significant challenges in quickly diagnosing critical conditions like heart attacks. Now, a new algorithm provides standardized assessments, aiding emergency room physicians in making confident clinical decisions about whether to rule in or rule out heart attacks.

Roche (Basel, Switzerland) has introduced the Chest Pain Triage algorithm, a CE-marked IVD medical device, as part of its navify Algorithm Suite. This suite is a cloud-based platform that hosts clinical algorithms from Roche and its partners, offering labs and hospitals seamless integration with Electronic Health Records (EHR) and Lab Information Systems (LIS), streamlining processes for faster and more efficient operations. Developed by Roche in collaboration with University Hospital Heidelberg (Heidelberg, Germany), the Chest Pain Triage algorithm is specifically designed to detect Acute Coronary Syndrome (ACS) more quickly and accurately in patients presenting with chest pain. The algorithm utilizes cutting-edge diagnostic technologies, including high-sensitivity cardiac troponin testing, to provide healthcare professionals with timely, reliable data to differentiate between cardiac and non-cardiac chest pain.

This advanced algorithm is part of Roche's comprehensive solution for addressing ACS, which also includes the cardiac troponin T Assay and integration with existing lab systems, offering an efficient approach to patient triage in emergency settings. The Chest Pain Triage algorithm is built to align with the European Society of Cardiology’s (ESC) guidelines, with input from top cardiologists and emergency medicine experts who contributed to its development. The algorithm is designed to accurately identify patients who are at genuine risk, distinguishing non-cardiac chest pain cases through a clear Rule-In, Rule-Out, or Observe recommendation based on the ESC guidelines. It simplifies decision-making by automatically selecting the appropriate ESC 0/1, 0/2, or 0/3 accelerated pathways, depending on the timing of the blood sample collection, which has the potential to reduce unnecessary hospital admissions and associated costs.

Additionally, the algorithm speeds up the treatment process for patients with true ACS by providing rapid assessments of chest pain onset, even if it occurred more than three hours before the first blood sample. It also offers a medical dossier to support clinicians and streamlines documentation by allowing easy transfer of recommendations and results into patient records. The Chest Pain Triage algorithm is part of Roche's broader commitment to the early identification and treatment of cardiovascular diseases. It is currently available in Europe, the Middle East, and Asia, with plans for future availability in the United States. Accessible through Roche's navify Algorithm Suite, the algorithm can be integrated into existing emergency department workflows. Roche's cardiometabolic portfolio aims to support quicker and more accurate triage decisions, with future ACS offerings combining next-generation digital algorithms, biomarkers, near-patient care devices, and laboratory analyzers.

"The introduction of our Chest Pain Triage algorithm underscores Roche's commitment to improving care for cardiovascular disease, one of the world’s largest health burdens," said Matt Sause, CEO, Roche Diagnostics. "One of the major challenges in managing chest pain in the emergency department is the length of stay, especially since some patients aren't actually having a heart attack. Our Chest Pain Triage algorithm can help doctors quickly decide who needs urgent cardiac care and who could be discharged sooner. With an early rule-out pathway, we can cut down Emergency Department visit times by over three hours.”


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
12-Channel ECG
CM1200B
New
Thoracolumbar & Sacropelvic System
Ennovate TLSP
New
Pedicle Screw Platform
CREO DLX Stabilization System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.